Itraconazol Altan

Itraconazole, the active ingredient in Itraconazol Altan, is a azole antifungal presented as a intravenous infusion solution for intravenous infusion use. It treats invasive fungal infections such as aspergillosis, candidemia and other systemic mycoses in immunocompromised patients.

GNH USA supplies Itraconazol Altan as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, providing reliable quality and regulatory compliance for critical care settings. The product meets EU pharmacopeial standards and is manufactured under GMP conditions.

Itraconazole is an azole antifungal used to treat systemic fungal infections by inhibiting ergosterol synthesis.

- Invasive aspergillosis: effective for treatment of life‑threatening lung and disseminated infections caused by Aspergillus species. - Candidiasis (including candidemia): used to clear bloodstream and deep‑tissue Candida infections. - Blastomycosis: indicated for severe blastomyces infections affecting lungs and other organs. - Histoplasmosis: employed in disseminated disease and severe pulmonary involvement. - Sporotrichosis: treats deep or disseminated Sporothrix infections resistant to oral therapy.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional episodes during infusion. - Abdominal pain: discomfort in the upper abdomen. - Headache: transient headache during or after infusion. - Rash: mild skin erythema or pruritus. - Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury requiring monitoring. - Severe hypersensitivity reactions: including anaphylaxis. - Cardiac failure: worsening of pre‑existing heart conditions. - Visual disturbances: blurred vision or photophobia. - QT prolongation: risk of arrhythmias, especially with other QT‑prolonging drugs.

Precautions for Itraconazol Altan include careful patient assessment and monitoring. - Liver function monitoring: assess baseline and periodic LFTs during therapy. - Drug interactions: review concomitant medications for CYP3A4 substrates or inhibitors. - Cardiac status: avoid in patients with known heart failure. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Itraconazol Altan may interact with several medicines; clinicians should assess risk.

Major Interactions (Avoid): - Rifampin: induces metabolism, markedly lowers itraconazole exposure. - Ketoconazole: competitive inhibition can raise itraconazole concentrations and toxicity. - Drugs that prolong QT interval (e.g., quinidine, sotalol): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Macrolide antibiotics (e.g., erythromycin, clarithromycin): may increase itraconazole levels. - CYP3A4 substrates (e.g., midazolam, sirolimus): require dose adjustment and monitoring.